Safety and target engagement profile of two oxaloacetate doses in Alzheimer's patients.

ABSTRACT:

Introduction

Brain bioenergetics are defective in Alzheimer's disease (AD). Preclinical studies find oxaloacetate (OAA) enhances bioenergetics, but human safety and target engagement data are lacking.

Methods

We orally administered 500 or 1000 mg OAA, twice daily for 1 month, to AD participants (n = 15 each group) and monitored safety and tolerability. To assess brain metabolism engagement, we performed fluorodeoxyglucose positron emission tomography (FDG PET) and magnetic resonance spectroscopy before and after the intervention. We also assessed pharmacokinetics and cognitive performance.

Results

Both doses were safe and tolerated. Compared to the lower dose, the higher dose benefited FDG PET glucose uptake across multiple brain regions (P < .05), and the higher dose

SUBMITTER: Vidoni ED 

PROVIDER: S-EPMC8084114 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature